FR940922-1-00081 FR940922-1-00009 (d) *␣*␣* (3) * * * A financial certification or disclosure statement as required by part 54 of this chapter must accompany all clinical data submitted. * * * * * * * * 11. Section 314.300 is amended in paragraph (b)(6) by adding a new sentence after the first sentence to read as follows: §314.300 Procedure for the issuance, amendment, or repeal of regulations. * * * * * (b) *␣*␣* (6) *␣*␣* A financial certification or disclosure statement as required by part 54 of this chapter must accompany all clinical data submitted with the request for hearing. *␣*␣* * * * * * PART 320_BIOAVAILABILITY AND BIOEQUIVALENCE REQUIREMENTS 12. The authority citation for 21 CFR part 320 continues to read as follows: Authority: Secs. 201, 501, 502, 505, 507, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 351, 352, 355, 357, 371). 13. Section 320.36 is amended by designating the existing text as paragraph (a) and by adding new paragraph (b) to read as follows: §320.36 Requirements for maintenance of records of bioequivalence testing. * * * * * (b) Any person who contracts with another party to conduct a bioequivalence study, the data of which are intended to be submitted to FDA as part of an application submitted under part 314 of this chapter, shall obtain from the person conducting the study sufficient accurate financial information to allow the submission of complete and accurate financial certifications or disclosure statements required under part 54 of this chapter and maintain that information and all records relating to the compensation given for that study and all other financial interest information required under part 54 of this chapter for 2 years after the date of approval for the application or, if the application is not approved, for 2 years after shipment and delivery of the drug which was the subject of the bioequivalence study. The person maintaining these records shall, upon request from any properly authorized officer or employee of the Food and Drug Administration, at reasonable times, permit such officer or employee to have access to and copy and verify these records. PART 330_OVER-THE-COUNTER (OTC) HUMAN DRUGS WHICH ARE GENERALLY RECOGNIZED AS SAFE AND EFFECTIVE AND NOT MISBRANDED 14. The authority citation for 21 CFR part 330 continues to read as follows: Authority: Secs. 201, 501, 502, 503, 505, 510, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 351, 352, 353, 355, 360, 371). 15. Section 330.10 is amended by adding new paragraph (f) to read as follows: §330.10 Procedures for classifying OTC drugs as generally recognized as safe and effective and not misbranded, and for establishing monographs. * * * * * (f) Financial certification or disclosure statement. Any clinical data submitted under this section must be accompanied by financial certifications or disclosure statements required by part 54 of this chapter. PART 601_LICENSING 16. The authority citation for 21 CFR part 601 continues to read as follows: Authority: Secs. 201, 501, 502, 503, 505, 510, 513&hyph;516, 518&hyph;520, 701, 704, 706, 801 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 351, 352, 353, 355, 360, 360c&hyph;360f, 360h&hyph;360j, 371, 374, 376, 381); secs. 215, 301, 351, 352 of the Public Health Service Act (42 U.S.C. 216, 241, 262, 263); secs. 2&hyph;12 of the Fair Packaging and Labeling Act (15 U.S.C. 1451&hyph;1461). 17. Section 601.2 is amended in paragraph (a) by adding a sentence after the first sentence to read as follows: §601.2 Applications for establishment and product licenses; procedures for filing. (a) *␣*␣* The applicant shall also include a financial certification or disclosure statement as required by part 54 of this chapter. * * * * * PART 807_ESTABLISHMENT REGISTRATION AND DEVICE LISTING FOR MANUFACTURERS AND DISTRIBUTORS OF DEVICES 18. The authority citation for 21 CFR part 807 continues to read as follows: Authority: Secs. 301, 501, 502, 510, 513, 515, 519, 520, 701, 704 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331, 351, 352, 360, 360c, 360e, 360i, 360j, 371, 374). 19. Section 807.31 is amended by adding new paragraph (d)(3) to read as follows: §807.31 Additional listing information. * * * * * (d) *␣*␣* (3) A copy of the certification or disclosure statement as required by part 54 of this chapter shall be retained and physically located at the establishment maintaining the historical file. * * * * * 20. Section 807.87 is amended by adding new paragraph (k) to read as follows: §807.87 Information required in a premarket notification submission. * * * * * (k) A financial certification or disclosure statement as required by part 54 of this chapter.
